

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A solid pharmaceutical composition offering a dual release and comprising at least two separate ~~regions~~portions,
 - [[a]]an extended release first ~~region~~portion comprising at least one non-steroidal anti-inflammatory drug (NSAID) ~~and mixed with~~ an adequate pharmaceutical carrier containing a retardant material for an extended release delivery of said non-steroidal anti-inflammatory drug (NSAID) presenting a controlled availability of the NSAID alongside the gastrointestinal track, and
 - [[a]]an second ~~region~~portion comprising a stabilized gastroprotective prostaglandin and an adequate pharmaceutical carrier for an immediate release of said stabilized gastroprotective prostaglandin.
 -
2. (Original) The pharmaceutical composition according to claim 1, wherein the first and the second ~~regions~~portions are separated by a third ~~region~~portion.
3. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the non-steroidal anti-inflammatory drug (NSAID) is selected from the group consisting of aceclofenac, diclofenac, diflunisal, fenbufen, flufenamic acid, ibuprofen, indomethacin, ketoprofen, meclofenamate sodium, meloxicam, mefenamic acid, nabumetone, naproxen, piroxicam, suprofen, tiaprofenic acid, acetylsalicylic acid, flurbiprofen, ketorolac, oxaprozin, sulindac, tenoxicam, tiaprofenic acid and suitable salts, ~~esters, amides, prodrugs or analogues~~ thereof.
4. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the retardant material of the first ~~region~~portion is selected from the group consisting of lipidic materials, acrylic and methacrylic acid polymers and copolymers, cellulose-based polymers and a mixture thereof.

5. (Currently Amended) The pharmaceutical composition according to claim 1, wherein the prostaglandin is a “E-series” prostaglandin selected from the group consisting of PGE1, PGE2, misoprostol, enoprostol, enisoprost, rosaprostol, ~~and miraprostol and analogues or derivatives thereof~~.

6. (Original) The pharmaceutical composition according to the claim 5, wherein the gastroprotective prostaglandin is misoprostol stabilized by a dispersion in hydroxypropylmethylcellulose (HPMC) or polyvinylpyrrolidone (PVP).

7. (Previously Presented) The pharmaceutical composition according to claim 1 which has a core tablet format comprising:

- a first ~~regionportion~~ being a core containing a therapeutically effective amount of NSAID and a retardant material for an extended release delivery of the NSAID and,
- a second ~~regionportion~~ being a mantle dry coating surrounding the core containing a therapeutically effective amount of a stabilized gestroprotective prostaglandin and a pharmaceutical carrier for an immediate release of said stabilized gestroprotective prostaglandin.

8. (Previously Presented) The pharmaceutical composition according to claim 1 which has a layered – or multilayered tablet format comprising:

- a first ~~regionportion~~ being a first layer containing a therapeutically effective amount of NSAID and a retardant material for an extended release delivery of the NSAID and,
- a second ~~regionportion~~ being a second layer containing a therapeutically effective amount of stabilized gastroprotective prostaglandin and a pharmaceutical carrier for an immediate release of said gastroprotective prostaglandin and, optionally
- a third ~~regionportion~~ being a third layer containing no active ingredient and separating the first and the second layers.

9. (Previously Presented) The pharmaceutical composition according to claim 1 which has a multiple units tablet format comprising:

- a first ~~regionportion~~ made of several units containing a therapeutically effective amount of NSAID and a retardant material for an extended release delivery of NSAID and,

- a second ~~regionportion~~ made of a powder of one or several units containing a therapeutically effective amount of stabilized gastroprotective prostaglandin and a pharmaceutical carrier for an immediate release said stabilized gastroprotective prostaglandin.

10. (Previously Presented) The pharmaceutical composition according to claim 1 which has a capsule format, ~~preferably made of the Hydroxypropylmethylcellulose (HPMC) polymer and~~ comprising:

- a first ~~regionportion~~ made of one or several units containing a therapeutically effective amount of NSAID and a retardant material for an extended release delivery of NSAID and,
- a second ~~regionportion~~ made of a powder of one or several units containing a therapeutically effective amount of stabilized gastroprotective prostaglandin and a pharmaceutical carrier for an immediate release of said of stabilized gastroprotective prostaglandin.

11. (Previously Presented) The pharmaceutical composition according to claim 1, wherein the non-steroidal anti-inflammatory drug (NSAID) is diclofenac, ketoprofen or naproxen and the stabilized gastroprotective prostaglandin is a stabilized misoprostol.

12. (Previously Presented) A method for the treatment and/or the prevention of inflammatory conditions or diseases in a mammal patient, including the human, that comprises the step of administrating a sufficient amount of the pharmaceutical composition according to claim 1, to said mammal patient.

13. (Original) The method according to claim 12, wherein said inflammatory condition or disease is osteoarthritis or rheumatoid arthritis.

14. (Previously Presented) The method of claim 12, wherein the pharmaceutical composition is administrated as dual release formulation allowing a one a day or twice a day dosing into humans.

15. (Canceled)

16. (New) A pharmaceutical composition comprising;

an extended-release portion made of one or several units containing therapeutically effective amounts of NSAIDs mixed with at least one retardant material for extended release delivery of the non-steroidal anti-inflammatory drugs (NSAIDs) presenting a controlled availability of the non-steroidal anti-inflammatory drug (NSAIDs) alongside the gastrointestinal tract;

an immediate release portion made of a powder of one or several units containing therapeutically effective amounts of the stabilised gastroprotective prostaglandin and a pharmaceutical carrier for the immediate release of said stabilised gastroprotective prostaglandin, and

wherein the extended release portion and the immediate release portion are encapsulated within a capsule made of hydroxyl-propyl-methyl-cellulose (HPMC) polymer.

17. (New) The pharmaceutical composition according to claim 10 which has a hydroxypropylmethylcellulose (HPMC) polymer capsule format.